

Financial news for ALIM dated on 2020-04-29: Alimera Sciences Q1 Sales \$14.535M Beat \$13.760M Estimate

Financial news for ALIM dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for ALIM dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for ALIM dated on 2020-04-23: Alimera Sciences Receives \$1.8M Loan Under Paycheck Protection Act

Financial news for ALIM dated on 2020-04-14: H.C. Wainwright Reiterates Buy on Alimera Sciences, Lowers Price Target to \$14

Financial news for ALIM dated on 2020-04-13: Alimera Sciences Sees Prelim. Q1 Sales Exceeding \$14M

Financial news for ALIM dated on 2020-04-07: 10 Biggest Price Target Changes For Tuesday

Financial news for ALIM dated on 2020-04-07: B. Riley FBR Maintains Buy on Alimera Sciences, Lowers Price Target to \$15

Financial news for ALIM dated on 2020-03-06: Alimera Sciences 8-K Shows Co. Received Letter From Nasdaq Informing It Has Regained Compliance

Financial news for ALIM dated on 2020-02-28: 140 Biggest Movers From Yesterday

Financial news for ALIM dated on 2020-02-27: 100 Stocks Moving In Thursday's Mid-Day Session

Financial news for ALIM dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lilly, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for ALIM dated on 2020-02-27: 40 Stocks Moving in Thursday's Pre-Market Session

Financial news for ALIM dated on 2020-02-26: 21 Stocks Moving In Wednesday's After-Hours Session

Financial news for ALIM dated on 2020-02-26: Alimera Sciences shares are trading higher after the company reported Q4 EPS results up from last year and better-than-expected sales results. The company also issued FY19 sales guidance above analyst estimates.

Financial news for ALIM dated on 2020-02-26: Alimera Sciences FY19 Sales \$53.94M Vs. \$50.85M Est.

Financial news for ALIM dated on 2020-02-26: Alimera Sciences Q4 EPS \$0.08 Up From \$(0.27) YoY, Sales \$17.348M Beat \$14.27M Estimate

Financial news for ALIM dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for ALIM dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for ALIM dated on 2020-01-27: 20 Specialty & Generic Drug Manufacturer Stocks Moving In Monday's Session

Financial news for ALIM dated on 2020-01-08: 48 Biggest Movers From Yesterday

Financial news for ALIM dated on 2019-12-17: 74 Biggest Movers From Yesterday

Financial news for ALIM dated on 2019-12-13: 51 Biggest Movers From Yesterday

Financial news for ALIM dated on 2019-12-11: Alimera Sciences 13D Filing From Ronald Chez Shows New 5.6% Stake

Financial news for ALIM dated on 2019-12-10: 80 Biggest Movers From Yesterday

Financial news for ALIM dated on 2019-12-09: 74 Biggest Movers From Friday

Financial news for ALIM dated on 2019-12-03: Alimera Announces Regulatory Approval for ILUVIEN in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

Financial news for ALIM dated on 2019-12-03: 75 Biggest Movers From Yesterday

Financial news for ALIM dated on 2019-11-29: 52 Biggest Movers From Wednesday

Financial news for ALIM dated on 2019-11-20: Alimera Sciences 13G Shows AIGH Capital Management Holds 9.3% Stake In Co.

Financial news for ALIM dated on 2019-11-19: 72 Biggest Movers From Yesterday

Financial news for ALIM dated on 2019-11-18: 44 Stocks Moving In Monday's Mid-Day Session

Financial news for ALIM dated on 2019-11-18: H.C. Wainwright Maintains Buy on Alimera Sciences, Raises Price Target to \$15

Financial news for ALIM dated on 2019-11-15: 70 Biggest Movers From Yesterday

Financial news for ALIM dated on 2019-11-13: Alimera Sciences Terminates Equity Purchase Agreement With Lincoln Park Capital Fund

Financial news for ALIM dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for ALIM dated on 2019-11-07: Alimera Sciences Announces Board's Approval Of 1-For-15 Reverse Stock Split Ratio

Financial news for ALIM dated on 2019-11-01: The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance

Financial news for ALIM dated on 2019-10-31: HC Wainwright & Co. Maintains Buy on Alimera Sciences, Lowers Price Target to \$1

Financial news for ALIM dated on 2019-10-29: Alimera Sciences Q3 EPS \$(0.04), Inline, Sales \$12.85M Beat \$12.79M Estimate

Financial news for ALIM dated on 2019-10-29: The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

Financial news for ALIM dated on 2019-10-25: Alimera Sciences Reports Equity Purchase Deal For Up To \$20M With Lincoln Park Capital

Financial news for ALIM dated on 2019-10-03: Alimera Reports Marketing Authorization for ILUVIEN In Portugal For Treatment Of Non-Infectious Posterior Uveitis

Financial news for ALIM dated on 2019-10-02: Alimera Sees Prelim. Q3 Sales Exceeding \$12.8M

Financial news for ALIM dated on 2019-10-01: Alimera Sciences To Present ILUVIEN Clinical Data At American Academy Of Ophthalmology Annual Meeting Oct. 12-15

Financial news for ALIM dated on 2019-09-12: Alimera Expands Deal With Horus Pharma To Including Marketing ILUVIEN In Benelux Countries

Financial news for ALIM dated on 2019-09-05: Alimera Sciences Board Of Directors Approves Reverse Stock Split And 10b5-1 Stock Purchase Plan For U.S. Executive Management

Financial news for ALIM dated on 2019-09-04: The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Financial news for ALIM dated on 2019-09-03: Alimera Sciences Launches ILUVIEN In Germany For Non-Infectious Uveitis Indication

Financial news for ALIM dated on 2019-08-28: The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

Financial news for ALIM dated on 2019-08-05: Alimera Announces ILUVIEN Regulatory Approval In Australia For The Treatment Of Diabetic Macular Edema

Financial news for ALIM dated on 2019-08-01: The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings

Financial news for ALIM dated on 2019-07-31: The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster

Financial news for ALIM dated on 2019-07-31: 28 Healthcare Stocks Moving In Tuesday's After-Market Session

Financial news for ALIM dated on 2019-07-30: Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Tue., July 30, 2019

Financial news for ALIM dated on 2019-07-30: New 52-Week Lows for Tuesday Morning

Financial news for ALIM dated on 2019-07-30: 45 Healthcare Stocks Moving In Monday's After-Market Session

Financial news for ALIM dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for ALIM dated on 2019-06-20: Alimera Sciences shares are trading higher after the company received a positive NICE recommendation for non-infectious Posterior Uveitis.

Financial news for ALIM dated on 2019-06-06: Alimera Reports 3-Year Trial Results For ILUVIEN Support Launch in Europe for the Prevention of Relapse in Recurrent Non-Infectious Uveitis Affecting the Posterior Segment

Financial news for ALIM dated on 2019-05-28: Craig-Hallum Initiates Coverage On Alimera Sciences with Buy Rating, Announces \$3 Price Target

Financial news for ALIM dated on 2019-05-22: Alimera Sciences Reports Launch Of Direct-To-Patient Marketing Campaign To Raise Awareness, Educate Consumers On Diabetic Macular Edema, ILUVIEN

Financial news for ALIM dated on 2019-04-29: Alimera Sciences Q1 EPS \$(0.04), Inline, Sales \$12.89M Beat \$12.28M Estimate

Financial news for ALIM dated on 2019-04-18: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for ALIM dated on 2019-04-17: Shares of several drug companies are trading lower amid continued efforts from Washington to curb prescription drug prices. The overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy.

Financial news for ALIM dated on 2019-02-19: Alimera Sciences On Monday Reported Q4 EPS \$(0.02) Beat \$(0.04) Estimate, Sales \$15.114M Beat \$12.59M Estimate

Financial news for ALIM dated on 2019-02-15: The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings

Financial news for ALIM dated on 2019-01-07: Alimera Sees FY18 GAAP Sales \$45M vs \$43.6M Est.

Financial news for ALIM dated on 2018-11-29: Alimera Sciences 8-K Shows CEO Daniel Myers To Retire, Will Serve As Non-Exec Chair; CFO Richard Eiswirth To Be Promoted To CEO Role

Financial news for ALIM dated on 2018-11-06: Alimera Sciences Late Monday Reported Q3 Adj. EPS \$(0.05) Beat \$(0.06) Estimate, Sales \$11.137M Beat \$10.98M Estimate

Financial news for ALIM dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for ALIM dated on 2018-07-30: Alimera Sciences Q2 EPS \$(0.06), Inline, Sales \$10.9M Beat \$10.75M Estimate

Financial news for ALIM dated on 2018-06-29: B. Riley FBR: 3 Reasons To Buy Alimera Sciences

Financial news for ALIM dated on 2018-06-29: B. Riley FBR Initiates Coverage On Alimera Sciences with Buy Rating, Announces \$2.75 Price Target

Financial news for ALIM dated on 2018-06-11: Alimera Sciences Reports UK National Institute For Health And Care Excellence Will Undertake Partial Review, Appraisal Of Technology Assessment 301 For ILUVIEN Reimbursement

Financial news for ALIM dated on 2018-06-04: Alimera Sciences Terminates \$25M At-the-Market Offering Agreement

Financial news for ALIM dated on 2018-05-31: Alimera Sciences Announces the Reimbursement of ILUVIEN in Spain

Financial news for ALIM dated on 2018-05-11: Benzinga's Daily Biotech Pulse: FDA Panel Nod For Akcea, Synergy's Revenue Miss, FDA Warns E-Liquid Makers Again

Financial news for ALIM dated on 2018-05-09: Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Financial news for ALIM dated on 2018-02-28: Alimera Sciences Reports Q4 EPS \$(0.09) vs \$(0.03) Est., Adj. EBITDA Loss \$3.8M, Sales \$9.1M vs \$12.2M Est.

Financial news for ALIM dated on 2018-01-04: Alimera Sciences Reports Received Acceptance Of Filing To Obtain Approval For ILUVIEN Non-Infectious Posterior Uveitis Indication In Europe

Financial news for ALIM dated on 2017-12-11: Alimera Sciences Reports Patients Are Now Being Treated With ILUVIEN In Ireland

Financial news for ALIM dated on 2017-11-01: Alimera Q3 \$(0.08) vs \$(0.05) Est., Sales \$9.78M vs \$10.68M Est.

Financial news for ALIM dated on 2017-10-20: Alimera Sciences 8-K Shows Registration For \$25M Common Stock Sale With HC Wainwright

Financial news for ALIM dated on 2017-09-12: Alimera Reports ILUVIEN Is Now Available In Ireland

Financial news for ALIM dated on 2017-09-11: Alimera Sciences Reports Co. Cancelled Previously-Announced Presentation, Webcast At Rodman & Renshaw Global Investment Conference Sept. 12, Cites 'Sever Tropical Storm Impacting Southeast'

Financial news for ALIM dated on 2017-08-29: Alimera Sciences Signs Agreement With Horus Pharma S.A.S As Exclusive Distributor of ILUVIEN in France

Financial news for ALIM dated on 2017-07-19: Alimera Sciences Announces UK Medicines and Healthcare Products Regulatory Agency Gives Final Approval To Reuce Size Of ILUVIEN Registry Safety Study

Financial news for ALIM dated on 2017-07-12: Alimera Sciences Reports ILUVIEN Now Being Given To Patients In Italy

Financial news for ALIM dated on 2017-07-10: UPDATE: pSivida Says Sales-Based Royalty Payments To Co. Will Start At 2%, Increases To 6% Upon Earliest Of 3 Events, Will Increase To 8% Based On ILUVIEN Sales In Excess Of \$75M In Any Calendar Year

Financial news for ALIM dated on 2017-07-10: UPDATE: pSivida Offers Key Terms Of Restructured Global Licensing Deal For ILUVIEN: Co. Grants Alimera Rights To Durasert In EMEA Under ILUVIEN Trademark In Exchange For Tiered Sales-Based Royalty Payments

Financial news for ALIM dated on 2017-05-08: Alimera Sciences Reports Q1 Adj. EBITDA Loss \$3.7M vs \$9.4M in Same Qtr. Last Year, EPS \$(0.10) vs \$(0.08) Est., Sales \$6.618M vs \$9.4M Est.

Financial news for ALIM dated on 2017-04-30: Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored

Financial news for ALIM dated on 2017-04-27: Benzinga's Top Upgrades, Downgrades For April 27, 2017

Financial news for ALIM dated on 2017-04-27: Rodman & Renshaw Initiates Coverage On Alimera Sciences with Buy Rating, Announces \$4.00 Price Target

Financial news for ALIM dated on 2017-03-13: Alimera Sciences Signs Agreement With Brill Pharma As Exclusive Distributor Of ILUVIEN In Spain

Financial news for ALIM dated on 2017-02-22: Alimera Sciences, Knight Therapeutics Report Filing of New Drug Submission for Iluvien in Canada

Financial news for ALIM dated on 2017-01-19: Armistice Capital Reports 5.2% Stake In Alimera Sciences

Financial news for ALIM dated on 2016-11-17: Stonepine Capital Reports 5.4% Passive Stake in Alimera Sciences in 13G

Financial news for ALIM dated on 2016-11-02: Alimera Sciences Reports Q3 Loss/Share \$0.16 vs Est Loss/Share \$0.11, Rev \$8.298M vs \$10.53M Est

Financial news for ALIM dated on 2016-10-20: Alimera Sciences Reports Facility Increased to \$45M, Interest Only Repayment Period Extended Up to 18 Mos.

Financial news for ALIM dated on 2016-09-16: 12 Biggest Mid-Day Gainers For Friday

Financial news for ALIM dated on 2016-09-16: Benzinga's Top Upgrades

Financial news for ALIM dated on 2016-09-16: Cowen & Co. Upgrades Alimera Sciences to Outperform

Financial news for ALIM dated on 2016-08-22: Great Point Partners Reports 5.12% Passive Stake in Alimera Sciences in 13G

Financial news for ALIM dated on 2016-08-11: Alimera Sciences Prices 18M Shares At \$1.40/Share

Financial news for ALIM dated on 2016-08-10: Alimera Shares Down 11% After Announcing Offering

Financial news for ALIM dated on 2016-08-10: Alimera Sciences Proposes Public Offering of Common Stock

Financial news for ALIM dated on 2016-08-04: 20 Biggest Mid-Day Losers For Thursday

Financial news for ALIM dated on 2016-08-04: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for ALIM dated on 2016-08-03: Alimera Sciences Reports Q2 Adj. EPS \$(0.17) vs \$(0.19) Est., Sales ~\$9.6M vs \$8.42M Est.

Financial news for ALIM dated on 2016-07-29: Option Alert: ALIM Jan17 2.5 Calls Sweep: 753 @ ASK \$0.65: 953 traded vs 1253 OI: Earnings 8/3 After Close \$2.02 Ref

Financial news for ALIM dated on 2016-07-28: Alimera Sciences Spikes to High on Volume

Financial news for ALIM dated on 2016-07-27: Alimera Sciences +15% Premarket @\$1.95

Financial news for ALIM dated on 2016-07-26: Mid-Afternoon Market Update: Crude Oil Drops Below \$43; Linear Technology Shares Spike Higher

Financial news for ALIM dated on 2016-07-26: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for ALIM dated on 2016-07-26: Mid-Day Market Update: Dow Falls 0.5%; EXACT Sciences Shares Rise Following Strong Q2 Results

Financial news for ALIM dated on 2016-07-26: Mid-Morning Market Update: Markets Mostly Higher; Caterpillar Tops Q2 Views

Financial news for ALIM dated on 2016-07-26: Alimera Sciences Reports Prelim Q2 Rev. \$9.3-\$9.5M vs. 7.24M

Financial news for ALIM dated on 2016-07-22: Stocks Hitting 52-Week Lows

Financial news for ALIM dated on 2016-05-06: Cowen & Company Downgrades Alimera Sciences to Market Perform

Financial news for ALIM dated on 2016-05-04: Alimera Sciences Reports Q1 EPS \$(0.22) vs. Est. \$(0.18), Rev. \$4.1M vs. Est. \$5.83M

Financial news for ALIM dated on 2016-04-21: Mid-Afternoon Market Update: Dow Falls 100 Points; Sarepta Therapeutics Shares Drop Following Release of FDA Briefing Documents on Eteplirsen

Financial news for ALIM dated on 2016-04-21: Watch Small Cap Biotech Shares On Alimera Halts, Companies up 5% Or Higher On The Day Include Inotek Pharmaceuticals, Avalanch Biotech, Opththotech

Financial news for ALIM dated on 2016-04-21: UPDATE: Alimera Shares Move Lower from Session Highs, Now Up 77% to ~\$3.34

Financial news for ALIM dated on 2016-04-21: pSividia Shares Trading Up \$0.33 To \$3.45/Share up 11% On The Day, Possibly In Sympathy With Alimera Sciences

Financial news for ALIM dated on 2016-04-21: Shares of Alimera Sciences Resume Trade Following Second Circuit Breaker Halt

Financial news for ALIM dated on 2016-04-21: Alimera Shares Resume Trade To High Of \$5.15, Now At \$4.12/Share

Financial news for ALIM dated on 2016-04-21: BZ NOTE: Alimera Sciences CEO Dan Myers Was Expected to Appear on FBN's Varney & Co. at 11:45 a.m. EDT

Financial news for ALIM dated on 2016-04-21: Shares of Alimera Halted on Circuit Breaker, Up 34.5%

Financial news for ALIM dated on 2016-03-04: Cantor Fitzgerald Maintains Buy on Alimera Sciences, Lowers PT to \$5.00

Financial news for ALIM dated on 2016-03-03: Mid-Morning Market Update: Markets Open Lower; Joy Global Reports Wider-Than-Expected Q1 Loss

Financial news for ALIM dated on 2016-03-02: Earnings Scheduled For March 2, 2016

Financial news for ALIM dated on 2016-01-05: Mid-Afternoon Market Update: Crude Oil Slides Over 2%; MannKind Shares Dip On Termination Of Afrezza Deal With Sanofi

Financial news for ALIM dated on 2016-01-05: Mid-Day Market Update: Dow Falls 50 Points; Smith & Wesson Shares Gain Following Strong Guidance

Financial news for ALIM dated on 2016-01-04: Alimera Science Says ILUVIEN J Code J7313 Now Active, Added To Healthcare Common Procedure Coding System, Confirms Pricing Entered Into Part B Avg. Sales Price

Financial news for ALIM dated on 2015-12-30: Mid-Day Market Update: Crude Oil Drops Over 3%; Sunedison Shares Spike Higher

Financial news for ALIM dated on 2015-12-17: Benzinga's M&A Chatter for Thursday December 17, 2015

Financial news for ALIM dated on 2015-12-17: Alimera Sciences Promotes Richard Eiswirth Jr. To CFO, C. Daniel Myers To Remain CEO of Company

Financial news for ALIM dated on 2015-12-17: UPDATE: Alimera Talking to Investment Banks Regarding Exploring Strategic Alternatives Including Potential Sale

Financial news for ALIM dated on 2015-12-17: Alimera Sciences Considering Sale -Reuters

Financial news for ALIM dated on 2015-12-15: Alimera Sciences Reports Signing of Deal to Distribute ILUVIEN in The Middle East

Financial news for ALIM dated on 2015-11-05: Alimera Sciences Reports Inline Q3 Loss \$0.21, Sales \$6.9M Vs Est \$6.96

Financial news for ALIM dated on 2015-10-30: 11 Stocks Moving In Friday's After-Hours Session

Financial news for ALIM dated on 2015-10-27: 13 Stocks To Watch In The Healthcare Space

Financial news for ALIM dated on 2015-10-22: Option Alert: \$ALIM Nov \$2.5 Put; 12500 Contracts @Ask @\$0.05

Financial news for ALIM dated on 2015-09-29: 3 Medical Tech Trading Ideas With Upcoming Catalysts

Financial news for ALIM dated on 2015-09-28: Alimera Reports Availability of Review Paper on Real World Experience with ILUVIEN

Financial news for ALIM dated on 2015-09-24: Alimera Sciences Limited Announces ILUVIEN(r) Study Results Presented At 15th Euretina Congress

Financial news for ALIM dated on 2015-08-13: Alimera Sciences Reports Signing of Exclusive ILUVIEN Distributor Deal for Italy, San Marino, Vatican City

Financial news for ALIM dated on 2015-08-10: Alimera Science Reports Q2 Loss \$0.19 Vs est Loss \$0.22, Sales \$5.78M Vs Est \$6.49M

Financial news for ALIM dated on 2015-08-10: Alimera Sciences Reports Q2 EPS \$(0.25) vs. Est. \$(0.22)

Financial news for ALIM dated on 2015-07-21: Alimera Sciences Announces They Have Signed Knight Therapeutics As Exclusive Distributor For ILUVIEN For Canada

Financial news for ALIM dated on 2015-05-07: Alimera Science Reports Q1 Loss \$0.27 Vs Est Loss \$0.24

Financial news for ALIM dated on 2015-04-21: Alimera Reports ILUVIEN Now Widely Available for Diabetic Macular Edema Patients Throughout US

Financial news for ALIM dated on 2015-04-14: Alimera Reports ILUVIEN Wins EMA in Poland

Financial news for ALIM dated on 2015-03-04: Alimera Solutions Reports Q4 EPS -\$0.23 Vs Est -\$0.17, Sales \$1.74M Vs Est \$5.11M

Financial news for ALIM dated on 2015-01-26: Alimera Shares Volatile Here Following Co. Release Announcing ILUVIEN Has Received Marketing Authorization in Finland, Luxembourg

Financial news for ALIM dated on 2015-01-15: Option Alert: ALIM July 2015 \$5 Put 5,000 Traded vs 65 OI

Financial news for ALIM dated on 2015-01-14: Alimera Sciences Announces First Sale of ILUVIEN In Portugal

Financial news for ALIM dated on 2014-12-01: pSivida Corp. Reports ILUVIEN Has Been Granted Marketing Authorization In The Netherlands

Financial news for ALIM dated on 2014-12-01: Alimera Sciences' ILUVIEN Receives Marketing Authorization In The Netherlands

Financial news for ALIM dated on 2014-11-28: Alimera Sciences Announces Agreement With Deerfield Management For \$50M Financing

Financial news for ALIM dated on 2014-11-17: Alimera Sciences Announces That The Irish Health Products Regulatory Authority (HPRA) Has Granted Marketing Authorization To ILUVIEN

Financial news for ALIM dated on 2014-11-06: Alimera Sciences, Inc. Reports Q3 EPS of \$(0.22) vs \$(0.70) Est; Revenue of \$2.41M vs \$3.75M Est

Financial news for ALIM dated on 2014-09-30: Alimera Reports Winning of \$25M Advance from Hercultes Technology Growth Capital

Financial news for ALIM dated on 2014-09-29: Alimera Sciences Inc Extends Gains On FDA News

Financial news for ALIM dated on 2014-09-29: Morning Market Movers

Financial news for ALIM dated on 2014-09-29: Benzinga's Top #PreMarket Gainers

Financial news for ALIM dated on 2014-09-29: Alimera Reports Iluvien Approved by FDA Without Restriction, Co. Sees Selling in US During Q1'15

Financial news for ALIM dated on 2014-09-26: Shares of Alimera, pSivida Resume Trade; Alimera Now Up 11%, pSivida Now Up 13%

Financial news for ALIM dated on 2014-09-26: Shares of Alimera Sciences, pSivida to Resume Trade at 4:45 p.m. EDT

Financial news for ALIM dated on 2014-09-26: Alimera Confirms FDA Approval for ILUVIEN

Financial news for ALIM dated on 2014-09-26: pSividia Confirms FDA Approval for ILUVIEN, Will Earn \$25M Milestone

Financial news for ALIM dated on 2014-09-26: Alimera, pSivida Have Won FDA Approval for Iluvien in DME

Financial news for ALIM dated on 2014-09-26: Alimera Sciences Halted: Pending News

Financial news for ALIM dated on 2014-09-22: 8-K from Alimera Sciences Shows Co. in Sales Pact with Cowen for \$35M in Shares

Financial news for ALIM dated on 2014-09-03: Alimera Sciences' Iluvien Wins Swedish Marketing Authorization for Chronic Diabetic Macular Edema

Financial news for ALIM dated on 2014-08-11: S-3 from Alimera Sciences Shows Registration for \$100M Mixed Securities Shelf

Financial news for ALIM dated on 2014-08-11: Alimera Sciences Files Up to \$100M Mixed Shelf

Financial news for ALIM dated on 2014-08-07: Alimera Sciences, Inc. Reports Q2 EPS of \$(0.16) vs \$(0.23) Est; Revenue of \$2.20M vs \$2.70M Est

Financial news for ALIM dated on 2014-07-31: Alimera Sciences' ILUVIEN Receives Marketing Authorization In Denmark for Treatment of Chronic DME

Financial news for ALIM dated on 2014-07-28: Alimera Sciences' ILUVIEN Receives Marketing Authorization In Norway for Treatment Of Chronic Diabetic Macular Edema

Financial news for ALIM dated on 2014-06-30: Morning Market Movers

Financial news for ALIM dated on 2014-06-30: Benzinga's Top #PreMarket Gainers

Financial news for ALIM dated on 2014-06-30: Alimera Sciences Announces Positive Iluvien Outcome For Repeat Use

Financial news for ALIM dated on 2014-05-08: Alimera Sciences, Inc. Reports Q1 EPS of \$(0.20) vs \$(0.25) Est; Revenue of \$2.08M vs \$1.15M Est

Financial news for ALIM dated on 2014-04-14: Alimera Sciences Announces Sept 26th PDUFA Date for ILUVIEN

Financial news for ALIM dated on 2014-03-27: Alimera Says Responded To Questions Raised In FDA CRL

Financial news for ALIM dated on 2014-03-26: Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast

Financial news for ALIM dated on 2014-03-07: Mid-Day Losers Mar. 7, 2014: PXLW, ALOG, ALSK, NMRX, NLNK, EMAN

Financial news for ALIM dated on 2014-03-07: Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower

Financial news for ALIM dated on 2014-03-07: Alimera Sciences Files to Sell Up to 6.25M Shares at \$6.85/Share -S-3

Financial news for ALIM dated on 2014-02-27: Alimera Sciences, Inc. Reports Q4 EPS of \$(0.24) vs \$(0.29) Est; Revenue of \$935.0K vs \$750.0K Est

Financial news for ALIM dated on 2014-01-28: Alimera Sciences Announces \$37.5M Private Placement

Financial news for ALIM dated on 2014-01-16: Is The Market On Drugs?

Financial news for ALIM dated on 2013-12-19: Morning Market Movers

Financial news for ALIM dated on 2013-12-19: Benzinga's Top #PreMarket Gainers

Financial news for ALIM dated on 2013-12-18: UPDATE: Alimera Shares Rise 65% After Hours as Co Enters Labeling Discussions with FDA on ILUVIEN

Financial news for ALIM dated on 2013-11-11: Alimera Sciences, Inc. Reports Q3 EPS of \$(0.04) vs \$(0.30) Est; Revenue of \$758.0K vs \$380.0K Est

Financial news for ALIM dated on 2013-10-28: Cowen & Company Upgrades Alimera Sciences, Inc. to Outperform

Financial news for ALIM dated on 2013-10-18: UPDATE: Alimera Falls 38%, pSivida Down 47% on FDA CRL for ILUVIEN

Financial news for ALIM dated on 2013-10-18: Alimera Sciences Receives FDA CRL for ILUVIEN

Financial news for ALIM dated on 2013-10-17: Another Leg Lower in pSivida, Alimera Shares as Traders Await Results of PDUFA

Financial news for ALIM dated on 2013-10-07: Northland Securities Initiates Coverage on Alimera Sciences, Inc. with Outperform, \$5.00 Target

Financial news for ALIM dated on 2013-08-12: Alimera Sciences, Inc. Reports Q2 EPS of \$(0.67) Which May Not Compare \$(0.24) Est

Financial news for ALIM dated on 2013-08-12: Earnings Scheduled For August 12, 2013

Financial news for ALIM dated on 2013-07-24: France's Transparency Commission Issues Positive Opinion For Reimbursement Of ILUVIEN(r)

Financial news for ALIM dated on 2013-06-17: Afternoon Market Gainers

Financial news for ALIM dated on 2013-06-14: A Peek Into The Market Before The Trading Starts

Financial news for ALIM dated on 2013-06-14: Alimera Sciences Announces Positive UK Appraisal Recommendation On ILUVIEN

Financial news for ALIM dated on 2013-03-21: Alimera Sciences, Inc. Reports Q4 EPS of



\$(0.17) vs \$(0.23) Est

Financial news for ALIM dated on 2013-03-21: Earnings Scheduled For March 21, 2013

Financial news for ALIM dated on 2013-01-17: Alimera Receives Marketing Authorization In Spain for ILUVIEN

Financial news for ALIM dated on 2012-11-30: UPDATE: Oppenheimer Reiterates Outperform Rating, Lowers PT on Alimera Sciences

Financial news for ALIM dated on 2012-11-30: Oppenheimer Reiterates Outperform on Alimera Sciences, Inc., Lowers PT to \$3.00

Financial news for ALIM dated on 2012-11-29: U.K.'s NICE Says Alimera's ILUVIEN Not Recommended for Treatment of Chronic Diabetic Macular Edema

Financial news for ALIM dated on 2012-11-07: Alimera Sciences Reports Q3 EPS \$-0.17 vs \$-0.18 Est

Financial news for ALIM dated on 2012-10-02: Alimera Sciences Closes \$40 Million Financing

Financial news for ALIM dated on 2012-07-26: Alimera Sciences' ILUVIEN Receives Marketing Authorization in Germany for the Treatment of Chronic Diabetic Macular Edema

Financial news for ALIM dated on 2012-07-18: A Peek Into The Market Before The Trading Starts

Financial news for ALIM dated on 2012-07-18: Alimera Sciences Agrees to Sell \$40 Million of Convertible Preferred Stock

Financial news for ALIM dated on 2012-06-05: Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in Portugal for the Treatment of Chronic Diabetic Macular Edema

Financial news for ALIM dated on 2012-05-11: Earnings Scheduled For May 11

Financial news for ALIM dated on 2012-04-24: Alimera Sciences Announces ILUVIEN Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema

Financial news for ALIM dated on 2012-03-23: Healthcare Investors And Capitalists Actively Looking For The Next Generation Of Market Movers -Reuters

Financial news for ALIM dated on 2012-03-05: Alimera Sciences Spiking Higher on Heavy Volume; Currently at \$4

Financial news for ALIM dated on 2012-02-28: Oppenheimer Increases Alimera Sciences PT

Financial news for ALIM dated on 2012-02-28: Alimera Sciences Rises 68% Pre-Market on Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN

Financial news for ALIM dated on 2012-02-28: Benzinga's Top Pre-Market Gainers

Financial news for ALIM dated on 2012-02-28: Financial Breakfast: Morning News Summary for February 28, 2012

Financial news for ALIM dated on 2012-02-28: Alimera Sciences Announces Positive Outcome to the European Decentralized Procedure for Approval of ILUVIEN for the Treatment of Chronic Diabetic Macular Edema

Financial news for ALIM dated on 2012-02-27: Benzinga's Microcap Movers for Monday February 27, 2012

Financial news for ALIM dated on 2012-02-27: Alimera Sciences Trading 29.8% Higher on Heavy Volume; Currently at \$2.22

Financial news for ALIM dated on 2011-12-12: Microcap Movers for Monday December 12, 2011

Financial news for ALIM dated on 2011-12-12: Alimera Sciences Company Spokesperson Says There is No News, No Press Releases to Account for Today's Price Movement

Financial news for ALIM dated on 2011-12-12: Alimera Sciences Spiking Higher on Heavy Volume

Financial news for ALIM dated on 2011-11-15: UPDATE: Credit Suisse Lowering Price

## Target on Alimera Sciences

Financial news for ALIM dated on 2011-11-15: Credit Suisse Downgrades Alimera Sciences to Neutral, PT Lowered to \$2

Financial news for ALIM dated on 2011-11-14: End-of-Day Market Summary for November 14, 2011

Financial news for ALIM dated on 2011-11-14: Citi Downgrading Alimera Sciences

Financial news for ALIM dated on 2011-11-14: Benzinga's Top Downgrades

Financial news for ALIM dated on 2011-11-14: Citigroup Downgrades Alimera Sciences to Neutral, Removes PT

Financial news for ALIM dated on 2011-11-11: Alimera Sciences Blindsided Again by CRL

Financial news for ALIM dated on 2011-11-11: Alimera Sciences Halted for Circuit Breaker

Financial news for ALIM dated on 2011-11-11: Alimera Sciences Resumes Trading

Financial news for ALIM dated on 2011-11-11: Alimera Sciences Halted for Circuit Breaker

Financial news for ALIM dated on 2011-11-11: Alimera Sciences Resumes Trading

Financial news for ALIM dated on 2011-11-11: PREVIEW: Alimera Sciences to Resume Trading at 12:50pm

Financial news for ALIM dated on 2011-11-11: UPDATE: FDA Said Unable to Approve Alimera Sciences ILUVIEN NDA

Financial news for ALIM dated on 2011-11-11: Alimera Sciences Receives Complete Response Letter From FDA for ILUVIEN

Financial news for ALIM dated on 2011-11-11: Alimera Sciences Halted for Pending News

Financial news for ALIM dated on 2011-11-03: Alimera Sciences Reports Q3 EPS \$(0.21) vs \$(0.19) Est

Financial news for ALIM dated on 2011-10-12: Alimera Sciences Highlights 36-Month FAME Study Data on ILUVIEN at AAO 2011 Annual Meeting

Financial news for ALIM dated on 2011-08-05: Rodman & Renshaw Maintain Market Outperform on Alimera Sciences

Financial news for ALIM dated on 2011-08-04: Alimera Sciences Reports Q2 EPS \$(0.17) vs \$(0.19) Est

Financial news for ALIM dated on 2011-08-01: Alimera Sciences Appoints James R. Largent to Its Board of Directors

Financial news for ALIM dated on 2011-06-01: Alimera Sciences Confirms ILUVIEN NDA Resubmission Has Been Accepted by the FDA

Financial news for ALIM dated on 2011-05-05: 36 Month Safety and Efficacy Data From the Phase 3 Fame Study of Iluvien (ALIM)

Financial news for ALIM dated on 2011-05-03: Alimera's New 36-Month Safety and Efficacy Results From the Phase 3 Fame Study of Iluvien in Patients With Diabetic Macular Edema Presented at the 2011 Arvo Annual Meeting (ALIM)

Financial news for ALIM dated on 2011-02-04: Citi Maintains Buy on Alimera Sciences (ALIM)

Financial news for ALIM dated on 2011-02-04: Oppenheimer Leaves Alimera Sciences PT, Outperform Rating Unchanged (ALIM)

Financial news for ALIM dated on 2010-12-28: CRL for Alimera's Eye drug - Analyst Blog

Financial news for ALIM dated on 2010-12-28: Alimera Sciences: Iluvien Approval Delayed By FDA

Financial news for ALIM dated on 2010-12-27: Afternoon Market Update

Financial news for ALIM dated on 2010-12-27: Google: Analysts' New Targets, Estimates

Financial news for ALIM dated on 2010-12-27: Benzinga's Top Pre-Market NASDAQ Losers (PSDV, TSLA, MGIC, NFLX)

Financial news for ALIM dated on 2010-12-27: A Peek Into The Market Before The Trading Starts

Financial news for ALIM dated on 2010-12-27: Credit Suisse Lowers PT On ALIM

Financial news for ALIM dated on 2010-12-27: Oppenheimer Has Outperform Rating On Alimera Sciences (ALIM)

Financial news for ALIM dated on 2010-11-30: Biotech Calendar: Key Dates for December

Financial news for ALIM dated on 2010-10-14: Mr. Yilun Jin Resigns as CFO of American Lorain Corporation

Financial news for ALIM dated on 2010-10-11: Rodman & Renshaw Initiates Coverage On ALIM, PUDA

Financial news for ALIM dated on 2010-08-31: ALIM: FDA Grants Iluvien NDA Priority Review

Financial news for ALIM dated on 2010-08-18: Citigroup Believes ALIM's Risk/Reward Tradeoff Is Favorable